Retatrutide Cost: $150 to $1,500/mo by Source (2026 Prices)

Skip the ranges. Enter your vial price, size, and weekly dose to see your real cost per month, the titration-ramp cost, and a full-course total, checked against tracked vendor prices.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly. Unlike tirzepatide, which targets two receptors (GIP + GLP-1), retatrutide activates three: GIP, GLP-1, and glucagon receptors. This triple mechanism is what makes it potentially more effective for weight loss, and what drives much of the interest in retatrutide among people already using GLP-1 medications.

In Phase 2 trials, participants on the highest dose (12mg weekly) lost an average of 24.2% of their body weight over 48 weeks, results that surpass both semaglutide and tirzepatide at their respective trial endpoints. The glucagon receptor component appears to contribute additional energy expenditure and fat oxidation beyond what GLP-1 and GIP provide alone.

Current Retatrutide Cost Landscape

Because retatrutide is not approved or commercially manufactured, there is no standard price. Clinical trials are the main lawful way to receive it. Lilly also runs a narrow expanded access program "for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial" (Reuters via KSL): adults 18 or older with a BMI of 35 or more despite tolerating the highest available dose of weight-management therapy, two or more serious or life-threatening obesity-related complications, no ability to join an ongoing retatrutide (or comparable) trial, and all standard options, including bariatric surgery, discussed (Lilly Medical; ClinicalTrials.gov NCT07629401). The treating physician applies to the FDA as the sponsor of a patient-specific investigational new drug (IND) application with institutional review board (IRB) approval, Lilly provides the drug at no cost, and there is no direct-to-patient shipping. It is not something a patient can buy. Outside these routes, people buy from research peptide vendors, and the FDA has warned companies for illegally selling retatrutide falsely labeled "for research purposes." Compounding pharmacies cannot lawfully supply it. For a complete breakdown of access routes, see our guide on how to get retatrutide. Here's the honest breakdown of what people are actually paying in early 2026.

Research Peptide Retatrutide: What It Actually Costs

The majority of people currently using retatrutide are sourcing it as a research peptide. This is the reality of the market, and the primary reason people search for "retatrutide cost." Here's what the pricing looks like.

Typical Vial Pricing

*Weeks of supply depends heavily on dose. At 1mg/week (starting), a 5mg vial lasts ~5 weeks. At 12mg/week (maximum clinical dose), it lasts less than 1 week.

Monthly Cost by Dose

Your actual monthly retatrutide cost depends entirely on your dose. The retatrutide dosing guide covers the Phase 2 titration schedule in detail, and the retatrutide cost calculator turns your own vial price into a cost per month, week, and milligram, but here's how dose affects cost:

Many people start with a microdosing approach, both to manage side effects and to keep costs lower during the initial weeks. At sub-clinical doses (0.5–2mg/week), monthly costs can stay below $100 with research peptides.

Grey market retatrutide: what people actually do

The "research peptide" label above covers a range of sources, but most retatrutide in circulation comes from a specific supply chain. This isn't an endorsement, it's a description of how the market works in 2026.

Where it comes from

Most research-grade retatrutide is synthesized by peptide manufacturers in China. These labs produce bulk powder, which vendors worldwide buy, vial, label, and resell. Some vendors operate domestically (US, EU) and charge more for local handling and faster shipping. Others sell direct from overseas at lower prices, but with longer shipping and customs risk.

How people find vendors

There's no directory or regulated marketplace. People find sources through:

• Reddit communities like r/Peptides and r/retatrutide, where users share vendor experiences, test results, and pricing
• Peptide forums where experienced users maintain vendor lists and flag bad actors
• Word of mouth through private groups and direct recommendations from people who've tested a source
• Group buys where communities organize bulk purchases to reduce per-vial cost

Vetting and quality

With no regulatory oversight, the peptide community has built its own quality control. The standard practice is third-party testing: you send a sample to an independent lab (Janoshik is the go-to) for HPLC and mass spectrometry analysis. Results show purity percentage, confirm the compound identity, and flag contaminants.

Reputable vendors share test results upfront. New vendors are treated with suspicion until someone independently verifies their product. The system has limits (testing costs $50-100 per sample), but it's the closest thing to a quality guarantee outside the pharma supply chain.

Grey market pricing

Risks specific to grey market sourcing

• Customs seizure: international shipments can be confiscated, particularly in countries with strict import rules on research chemicals. Most vendors reship if this happens, but it adds weeks of delay.
• Purity and dosing uncertainty: without third-party testing, you don't know what's in the vial. Underfilled and overfilled vials, degraded peptide from poor cold-chain handling, and outright fakes have all been documented.
• No medical oversight: you're self-administering an unapproved compound with no prescriber involved. If something goes wrong, you're on your own.
• No legal recourse: if a vendor sends a bad product or disappears with your money, there's no consumer protection. Community reputation is the only enforcement mechanism.
• Payment methods: most grey market vendors don't accept credit cards. Expect cryptocurrency, wire transfers, or payment apps, all harder to dispute.

Compounded Retatrutide Pricing: Not a Lawful Option

Unlike the compounded semaglutide and compounded tirzepatide markets, there is no lawful compounded retatrutide to price. The FDA states: "Retatrutide and cagrilintide cannot be used in compounding under federal law." Compounding pharmacies (503A or 503B) cannot lawfully supply it, and a prescription does not change that.

What to Expect

• Monthly cost: None. There is no lawful compounded product, so any quoted compounded price is for an unlawful product
• Enforcement: The FDA has warned telehealth companies for marketing retatrutide, API distributors for selling it to compounders, and outsourcing facilities for repackaging it
• Lawful alternative: Enrollment in a clinical trial, which is free
• Details: See our compounded retatrutide explainer

Compounded vs Research Peptides

Neither column is a lawful route. If you want retatrutide with a prescriber monitoring your progress and side effects, a clinical trial is the main lawful way to get it (the only other lawful route is Lilly's narrow, physician-requested expanded access program).

Projected Commercial Retatrutide Cost

When Eli Lilly brings retatrutide to market (likely in 2027 or 2028), it will carry a brand-name price. No official guidance exists, but we can make reasonable projections based on Lilly's existing products and the competitive landscape.

Pricing Benchmarks

Why $1,000–$1,500? Retatrutide has a more advanced mechanism than tirzepatide, and Lilly will price it accordingly. But the GLP-1 market is getting crowded, and oral alternatives and multiple new injectables are in the pipeline, which could push pricing toward the lower end of that range. Lilly's approach with Mounjaro/Zepbound suggests competitive pricing with a premium for the triple-agonist data.

Retatrutide vs Tirzepatide vs Semaglutide: Cost Comparison

Here's how retatrutide cost stacks up against the two most commonly used GLP-1 class medications across all available sourcing options. For a deeper look at the efficacy differences, see our retatrutide vs tirzepatide comparison.

The tradeoff is clear: retatrutide has the best weight loss data but also the most uncertainty: no FDA approval, no standardized commercial product, and no lawful access outside clinical trials and Lilly's narrow expanded access program. Use the retatrutide calculator to model your dosing schedule and estimate your ongoing supply needs.

Insurance and Coverage Outlook

Since retatrutide is not approved, no insurance plan covers it. But when it reaches the market, here's what to expect based on the current GLP-1 insurance landscape:

If Approved for Type 2 Diabetes

• Most commercial insurance plans will cover it, especially if it demonstrates A1C reduction comparable to or exceeding tirzepatide
• Prior authorization will likely be required
• Step therapy (try metformin first, then other agents) is standard
• Copays with manufacturer savings: potentially $25–$50/month

If Approved for Obesity/Weight Management

• Coverage remains highly variable, and many plans still exclude weight management medications
• Medicare Part D: Congress has been debating coverage of anti-obesity medications, but it remains excluded as of early 2026
• Self-insured employers increasingly adding GLP-1 coverage, but it's employer-specific
• Expect significant prior authorization requirements (BMI thresholds, failed diet attempts)

The practical reality: even when retatrutide is approved, many people will face the same insurance barriers that currently exist for Wegovy and Zepbound. Do not expect a compounded fallback like the ones that exist for semaglutide and tirzepatide: the FDA states retatrutide cannot be used in compounding under federal law.

Getting Retatrutide Through Clinical Trials

Clinical trials and Lilly's expanded access program both provide pharmaceutical-grade retatrutide at no cost; expanded access is narrow and must be requested by a physician. Most retatrutide Phase 3 trials are no longer enrolling (check ClinicalTrials.gov for open studies). Eli Lilly's TRIUMPH Phase 3 program included multiple trials across different populations:

• TRIUMPH-1: Obesity without type 2 diabetes (NCT05929066)
• TRIUMPH-2: Obesity with type 2 diabetes
• Additional trials: MASLD/NASH, cardiovascular outcomes, kidney outcomes

What Trial Enrollment Includes

• Free study medication (retatrutide or placebo; you may receive placebo)
• Regular medical monitoring, blood work, and assessments
• Compensation for time and travel in most trials
• Access to the latest clinical data and follow-up care

How to Reduce Retatrutide Costs

Until commercial availability, here are practical strategies to manage what you spend on retatrutide:

1. Start Low, Titrate Slowly

The standard titration protocol starts at 1mg/week and escalates gradually. At starting doses, your monthly cost is a fraction of what it costs at 8mg or 12mg. Many users find meaningful effects at moderate doses (4–8mg) without needing to push to the maximum. Use the retatrutide calculator to visualize blood levels at different doses, and you may find your sweet spot at a lower (and cheaper) dose.

2. Buy Larger Vials

Per-milligram pricing drops significantly with larger vial sizes. A 10mg vial costs less per mg than two 5mg vials. If you've dialed in your dose and know your monthly need, buying larger quantities reduces cost per dose.

3. Consider Microdosing

Some users experiment with microdosing retatrutide at sub-clinical doses (0.25–1mg/week). At these levels, a single 5mg vial can last 5–20 weeks, dropping monthly costs well below $50. The efficacy data at these doses is limited, but some users report noticeable appetite suppression even at low doses due to the triple-agonist mechanism.

4. Use Proper Reconstitution and Storage

Wasted peptide is wasted money. Follow the reconstitution guide carefully, store properly at 2–8°C after reconstitution, and use our reconstitution calculator to ensure accurate dosing so you're not over-injecting.

5. Check Clinical Trial Eligibility

If you meet the criteria, clinical trials provide free pharmaceutical-grade retatrutide with full medical supervision. It's the gold standard access path. The tradeoff is the possibility of receiving placebo and the time commitment of study visits.